Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

85.29USD
24 Sep 2018
Change (% chg)

$-0.17 (-0.20%)
Prev Close
$85.46
Open
$85.31
Day's High
$85.50
Day's Low
$84.92
Volume
1,812,051
Avg. Vol
1,745,373
52-wk High
$94.19
52-wk Low
$72.30

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $217,842.00
Shares Outstanding(Mil.): 2,550.62
Dividend: 2.94
Yield (%): 3.18

Financials

  NVS Industry Sector
P/E (TTM): 14.56 30.48 32.69
EPS (TTM): 5.87 -- --
ROI: 12.45 13.04 12.72
ROE: 18.79 14.99 14.85

BRIEF-Novartis - Positive CHMP Opinion For Sandoz' Biosimilar Pegfilgrastim

* SANDOZ RECEIVES POSITIVE CHMP OPINION FOR PROPOSED BIOSIMILAR PEGFILGRASTIM

Sep 21 2018

BRIEF-Novartis Wins Positive CHMP Opinion For Luxturna To Treat Rare Inherited Retinal Disease

* ANNOUNCES POSITIVE CHMP OPINION FOR ONE-TIME GENE THERAPY LUXTURNA® TO TREAT CHILDREN AND ADULTS WITH RARE INHERITED RETINAL DISEASE Source text for Eikon: Further company coverage:

Sep 21 2018

BRIEF-Novartis Wins Positive CHMP Opinion For Gilenya For MS In Children

* NOVARTIS RECEIVES POSITIVE CHMP OPINION FOR GILENYA® FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH MS, MARKING A MAJOR MEDICAL ADVANCE FOR YOUNG MS PATIENTS IN EUROPE Source text for Eikon: Further company coverage:

Sep 21 2018

Spark's Luxturna blindness therapy gets European panel nod

ZURICH, Sept 21 A European Medicines Agency panel recommended approval of Spark Therapeutics' gene therapy for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world's costliest treatments outside the United States.

Sep 21 2018

BRIEF-Ubiome Appointed Joseph Jimenez To Its Board

* UBIOME - APPOINTED JOSEPH JIMENEZ, FORMER CEO OF NOVARTIS, TO ITS BOARD Source text for Eikon: Further company coverage:

Sep 21 2018

UPDATE 1-UK rejects adult Novartis CAR-T therapy, after 'yes' in kids

LONDON, Sept 19 Health authorities in England have rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing its use in children and young people.

Sep 19 2018

Novartis links bonuses to ethics in bid to rebuild reputation

ZURICH Swiss drugmaker Novartis has revealed its employees only get a bonus if they meet or exceed expectations for ethical behavior as it seeks to address past shortcomings that have damaged its reputation.

Sep 17 2018

Novartis links bonuses to ethics in bid to rebuild reputation

ZURICH, Sept 17 Swiss drugmaker Novartis has revealed its employees only get a bonus if they meet or exceed expectations for ethical behaviour as it seeks to address past shortcomings that have damaged its reputation.

Sep 17 2018

Swiss stocks - Factors to watch on Sept. 17

ZURICH/BERLIN, Sept 17 The Swiss blue-chip SMI was seen opening 0.1 percent lower at 8,965 points on Monday, according to premarket indications by bank Julius Baer .

Sep 17 2018

Alcon picks Geneva over Texas for new HQ

ZURICH The headquarters of Alcon, the eyecare unit of Novartis which will be spun off to shareholders in 2019, will move from the division's longtime corporate home in the Dallas suburbs to the Swiss city of Geneva, Novartis said in a statement on Tuesday.

Sep 11 2018

Competitors

Earnings vs. Estimates